Literature DB >> 21297477

Management of the neck in metastatic cutaneous squamous cell carcinoma of the head and neck.

Jacob D'Souza1, Jonathan Clark.   

Abstract

PURPOSE OF REVIEW: This article reviews the predictors, prognosis, and treatment of nodal metastases in cutaneous squamous cell carcinoma of the head and neck. RECENT
FINDINGS: There is a better understanding of the risk factors that predict metastatic disease in cutaneous squamous cell carcinoma. Recent data has simplified the relationship between the site of the primary tumour and nodal disease, allowing for a more selective approach to the neck, in terms of both surgery and radiotherapy. Newer staging systems that take into account the clinicopathological factors allow better prognostication, and their application has been discussed. There is ongoing research on concurrent chemoradiotherapy, sentinel node biopsy, and epidermal growth factor receptor overexpression.
SUMMARY: The status of the parotid and level II/III nodes has important implications for the management of the neck, and therefore dissection of level I and level IV/V nodes is required in selected cases only. Prognostic stratification is needed to tailor treatment algorithms that intensify therapy in high-risk disease and minimize toxicity in selected low-risk patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21297477     DOI: 10.1097/MOO.0b013e328343e811

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  8 in total

1.  [Not Available].

Authors:  Bruna Melhoranse Gouveia; Maria Helena de Magalhães Barbosa; Leonardo Hoehl Carneiro; Luzia Abrao El Hadj; Nurimar Conceição Fernandes
Journal:  An Bras Dermatol       Date:  2016 May-Jun       Impact factor: 1.896

2.  The role of elective superficial parotidectomy in the treatment of temporal region squamous cell carcinoma.

Authors:  Sameep Kadakia; Yadranko Ducic; Diego Marra; Masoud Saman
Journal:  Oral Maxillofac Surg       Date:  2015-12-21

3.  Metastases to the parotid nodes: CT and MR imaging findings.

Authors:  Nobuo Kashiwagi; Takamichi Murakami; Masafumi Toguchi; Katsuyuki Nakanishi; Shojiro Hidaka; Hideyuki Fukui; Masatomo Kimura; Mutsukazu Kitano; Noriyuki Tomiyama
Journal:  Dentomaxillofac Radiol       Date:  2016-10-11       Impact factor: 2.419

4.  The Effect of Tumor Characteristics and Location on the Extent of Lymph Node Metastases of Head and Neck Cutaneous Squamous Cell Carcinoma.

Authors:  Bram van Leer; Alet J G Leus; Boukje A C van Dijk; Marloes S van Kester; Gyorgy B Halmos; Gilles F H Diercks; Bert van der Vegt; Jeroen Vister; Emoke Rácz; Boudewijn E C Plaat
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

Review 5.  High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Clinical Review.

Authors:  Flora Yan; Brittny N Tillman; Rajiv I Nijhawan; Divya Srivastava; David J Sher; Vladimir Avkshtol; Jade Homsi; Justin A Bishop; Erin M Wynings; Rebecca Lee; Larry L Myers; Andrew T Day
Journal:  Ann Surg Oncol       Date:  2021-06-30       Impact factor: 5.344

6.  The treatment of neck and parotid gland in cutaneous squamous cell carcinoma of face and forehead and the review of literature.

Authors:  Mehmet Haksever; Davut Akduman; Mustafa Demir; Sündüs Aslan; Muhammed Yanılmaz; Fevzi Solmaz
Journal:  Ann Med Surg (Lond)       Date:  2015-02-07

7.  Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: A pilot study.

Authors:  Tia Morosin; Bruce Ashford; Marie Ranson; Ruta Gupta; Jonathan Clark; N Gopalakrishna Iyer; Kevin Spring
Journal:  Oncotarget       Date:  2016-07-26

8.  Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma.

Authors:  Elahe Minaei; Simon A Mueller; Bruce Ashford; Amarinder Singh Thind; Jenny Mitchell; Jay R Perry; Benjamin Genenger; Jonathan R Clark; Ruta Gupta; Marie Ranson
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.